Tamoxifen

Pioneering Medicine in Breast Cancer

  • Philipp Y. Maximov
  • Russell E. McDaniel
  • V. Craig Jordan

Part of the Milestones in Drug Therapy book series (MDT)

Table of contents

  1. Front Matter
    Pages i-xxii
  2. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 1-30
  3. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 31-46
  4. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 47-67
  5. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 69-84
  6. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 85-99
  7. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 101-114
  8. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 115-134
  9. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 135-142
  10. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 143-163
  11. Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
    Pages 165-178
  12. Back Matter
    Pages 179-199

About this book

Introduction

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.

This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

Keywords

Anti-estrogens Apoptosis Breast cancer Estrogen receptor SERMs

Authors and affiliations

  • Philipp Y. Maximov
    • 1
  • Russell E. McDaniel
    • 1
  • V. Craig Jordan
    • 1
  1. 1.Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington, DCUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-0348-0664-0
  • Copyright Information Springer Basel 2013
  • Publisher Name Springer, Basel
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-0348-0663-3
  • Online ISBN 978-3-0348-0664-0
  • Series Print ISSN 2296-6056
  • Series Online ISSN 2296-6064
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma